All News

RheumNow Podcast square

Methotrexate Nodulosis (1.19.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. How good (or not) are rheumatologists and what to do about MTX nodulosis?

Read Article
RheumNow Podcast square

New Year's Resolutions (1.5.2024)

Jack Cush, MD

Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Stillsnow, Stills, podcast

StillsNow Podcast December 2023 - ACR23 Highlights

Jack Cush, MD

Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023 Annual meeting held in San Diego, November 12th thru 16th.

Read Article
CSS Storm Cytokine

Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

Jack Cush, MD

A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to halt disease progression and prevent life-threatening complications from HLH/MAS.

Read Article
rare

ICYMI: Here at Last: Treatment Options for VEXAS

Michael Putman, MD, MSCI

We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.

Read Article
@RheumNow #RNL2024 Winthrop: JAKi similar for opportunistic disease, but higher risk for Herpes Zoster than other therapies Deucravacitinib - lower HZ reported, but younger age. Will see if this holds case in more studies https://t.co/Nd5LitAI3R

Links:

Eric Dein ericdeinmd ( View Tweet)
So why should you consider JAKi? Multiple reasons provided by @JointMD including efficacy in domains, it's PO, reasonable safety. #RNL2024 @RheumNow https://t.co/BgFjhb18Ad

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
JAKi toxicities of interest: - Zoster - Safety: VTE, MACE, Malignancies - Lab abnormalities including CK, LFT, creatinine, and lipid elevations and cytopenias. @JointMD #RNL2024 @rheumnow https://t.co/u72yz8uLYB

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
@JointMD reviews the pros and cons of JAKi at #RNL2024 @RheumNow https://t.co/z9CSvP5BAZ

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Many advanced treatments appear to work less well in female patients with PsA, but JAKi seem to not demonstrate this phenomenon. Not sure what to do with this data in clinical practice but it is certainly intriguing @lihi_eder @RheumNow #RNL2024 https://t.co/GDrg715ctg

Links:

Richard Conway RichardPAConway ( View Tweet)
Key take home points from @_AprilArmstrong on psoriatic disease @RheumNow #RNL2024 https://t.co/Svx9gNKBuR

Links:

Richard Conway RichardPAConway ( View Tweet)
ICYMI: new guidelines published in 2019 for CV prevention. It's important to assess CV risk in our patients because inflammatory diseases is now included as a risk factor (helps when deciding on starting pts on JAKi)- Dr. B Weber #RNL2024 @RheumNow https://t.co/nBQjs49avu https://t.co/apyDjaxudi

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Japanese retrospective study compared RA pts on JAK inhib vs bDMARDs (n=62 ea) having orthopedic surgery; JAKi- pts had more postoperative flares (29% v 12%, P=.01), esp if JAKi held >11d (p.04). No diff in other postop complications https://t.co/NVY1Oajdve https://t.co/fwc9KWYZ9l

Links:

Dr. John Cush RheumNow ( View Tweet)
Experience the Future of Rheumatology at RheumNow Live 2024, just two weeks away! Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights. https://t.co/bbnb97MOHO https://t.co/QXO34ZmP2i

Links:

Dr. John Cush RheumNow ( View Tweet)
Experience the Future of Rheumatology at RheumNow Live 2024, just three weeks away! Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights. https://t.co/HN8ErCpSMb https://t.co/kCYD7Hbhxx

Links:

Dr. John Cush RheumNow ( View Tweet)
Anti-TNF mAbs, JAKi & anti-IL17 Rx appear protective against anterior Uveitis in AxSpA pts. Network Metanalysis of 44 trials, AU IR -TNF mAb: 4.1, ETN: 5.4, IL17i: 2.8, JAKi: 1.5, & placebo: 10.8. AU risk: TNFi < JAKi < IL-17i < ETN << PBO https://t.co/3zIcvuIaBV https://t.co/UseZ6t00EB

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/wOZh9qGQZD https://t.co/ODNcDHp1iU

Links:

Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/LNIqQxQFKK

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2023 - Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/Uh2RFrfpc2

Links:

Dr. John Cush RheumNow ( View Tweet)

Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now a report of 21 PPP pts given bimekizumab and 17 patients showed complete clearance in 1 to 4 months. SAPHO pts had complete clearance of skin & improved joint pain https://t.co/tYpHCxFOBI https://t.co/i4o3KnGlPY

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×